Business Context and Reporting Period
This Form 8-K reports on the 2017 Annual Meeting of Stockholders held by Corvus Pharmaceuticals, Inc. on June 8, 2017. The meeting took place at the company's principal executive offices in Burlingame, California. As of the record date (April 17, 2017), there were 20,934,514 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and stockholder voting results.
Material Changes and Voting Results
A total of 19,075,230 shares were voted in person or by proxy. The results for the four proposals were as follows:
- Proposal 1 (Election of Directors): Class I nominees Richard A. Miller, M.D., and Peter Moldt, Ph.D., were elected. Both received over 16.6 million votes "For" with approximately 1.1 million votes "Withheld."
- Proposal 2 (Ratification of Accounting Firm): Stockholders ratified the selection of PricewaterhouseCoopers LLC. Votes were 19,067,516 "For," 2,593 "Against," and 5,121 "Abstain."
- Proposal 3 (Amended and Restated Certificate of Incorporation): Stockholders ratified the amendment. Votes were 15,567,724 "For," 3,488,903 "Against," and 18,603 "Abstain."
- Proposal 4 (Amended and Restated Bylaws): Stockholders ratified the amendment. Votes were 15,566,496 "For," 3,490,181 "Against," and 18,553 "Abstain."
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, or contingencies. The document serves solely to disclose the outcome of the stockholder vote.
Important Facts for Investors to Verify
- Verify the specific terms of the Amended and Restated Certificate of Incorporation and Bylaws approved in Proposals 3 and 4, as these received significant "Against" votes (approximately 3.49 million shares each).
- Confirm the tenure of the newly elected Class I directors, who will serve until the 2020 Annual Meeting.
- Review the Definitive Proxy Statement on Schedule 14A filed on April 24, 2017, for detailed descriptions of the proposals and the rationale behind the amendments.